

Statutory Approvals Committee - minutes

Centre 0102 (Guys Hospital) – PGD application for Antithrombin III Deficiency OMIM #613118

Friday, 24 June 2016

HFEA, Level 2, 10 Spring Gardens, London, SW1A 2BU

Committee members	David Archard (Chair) Rebekah Dundas (Deputy Chair) Margaret Gilmore Anthony Rutherford Anne Lampe Ruth Wilde	
Members of the Executive	Ian Brown Trent Fisher	Head of Corporate Governance Secretary
External adviser	Jenny Carmichael	
Legal Adviser	Dawn Brathwaite	Mills & Reeve LLP
Observers	None	

Declarations of interest:

- members of the committee declared that they had no conflicts of interest in relation to this item.

The committee had before it:

- 8th edition of the HFEA Code of Practice
- standard licensing and approvals pack for committee members

The following papers were considered by the committee:

- executive summary
- PGD application form
- redacted peer review
- Genetic Alliance opinion

1. Consideration of application

- 1.1. The committee welcomed the advice of its specialist advisor, Dr Jenny Carmichael, who confirmed that the condition is as described in the papers. Dr Carmichael informed the committee that the condition causes a higher than average risk of developing abnormal blood clots.
- 1.2. The committee noted that the condition can cause blood clots, deep vein thrombosis, pulmonary embolism which can be fatal or cause long lasting problems.
- 1.3. The committee noted that the treatment for the condition includes medications such as Warfarin to lower chances of clotting. Antithrombin concentrates, both plasma derived and recombinant, can be used to restore low levels in emergency situations or prior to surgery.
- 1.4. The committee felt that they lacked the detailed information regarding the current treatment options available for the condition.
- 1.5. The committee noted that papers stated there was an estimated 50 to 85 percent chance of individuals with this condition having one or more thrombotic event within their lifetime.


2. Decision

- 2.1. The committee agreed that they did not have sufficient information to make an informed decision.
- 2.2. The committee requests that they are provided with:
 - an opinion of a haematologist to include information regarding the treatment options available and the associated risks and impact related to the treatment options
 - a breakdown of the proportions of thrombotic events by life threatening events, events causing serious long term problems and less serious events

3. Chair's signature

- 3.1. I confirm this is a true and accurate record of the meeting.

Signature



Name

David Archard

Date

11 July 2016